Acelrx announces $14 million registered direct common stock and warrant offering

Hayward, calif., nov. 15, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx) (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into an agreement with two life sciences-focused investment funds that are existing and new stockholders in acelrx, for the sale of 17,500,000 shares of common stock and warrants exercisable for an aggregate of 17,500,000 shares of common stock.
ACRX Ratings Summary
ACRX Quant Ranking